Role of the PI 3-kinase signaling pathway in cell regulation and human disease [electronic resource] / Lewis Cantley.

By: Cantley, Lewis [spk]Material type: FilmFilmSeries: Henry Stewart talksBiomedical & life sciences collection. Protein phosphorylation: Publisher: London : Henry Stewart Talks, 2010Description: 1 online resource (1 streaming video file (32 min.) : color, sound)Subject(s): Phosphatidylinositol 3-Kinases | Signal TransductionOnline resources: Click here to access online | Series
Contents:
Contents: Phosphoinositide 3-kinase (PI3K) signaling -- Class Ia PI3K's and the mediation of growth factor signaling -- The receptor tyrosine kinase signaling pathway -- Loss-of-function mutations in tumor suppressors -- Sporadic mutations -- Drug targets -- Regulation of metabolism by PI3K AKT signaling -- Targets of the drug NVP BEZ235 -- Generation of mice with mutant PI3K p110a -- How lung adenocarcinoma requires mutant PI3K -- HIF-1alpha -- Visualizing lung tumors using FDG PET -- How mTOR inhibition does not reduce tumor volume -- Will a PI3K inhibitor kill K-Ras driven tumors? -- How AKT inhibition does not affect tumor size or activity -- Effects of BEZ235 in K-Ras mutant tumors -- How BEZ235 specifically kills PI3K driven tumors -- The drug ARRY 886 -- How PI3K with MEK inhibitors eradicates K-Ras tumors -- Blocking the PI3K and MAP Kinase pathways -- Inhibition of S6 kinase in K-Ras tumors.
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
No physical items for this record

Animated audio-visual presentation with synchronized narration.

Title from title frames.

Contents: Phosphoinositide 3-kinase (PI3K) signaling -- Class Ia PI3K's and the mediation of growth factor signaling -- The receptor tyrosine kinase signaling pathway -- Loss-of-function mutations in tumor suppressors -- Sporadic mutations -- Drug targets -- Regulation of metabolism by PI3K AKT signaling -- Targets of the drug NVP BEZ235 -- Generation of mice with mutant PI3K p110a -- How lung adenocarcinoma requires mutant PI3K -- HIF-1alpha -- Visualizing lung tumors using FDG PET -- How mTOR inhibition does not reduce tumor volume -- Will a PI3K inhibitor kill K-Ras driven tumors? -- How AKT inhibition does not affect tumor size or activity -- Effects of BEZ235 in K-Ras mutant tumors -- How BEZ235 specifically kills PI3K driven tumors -- The drug ARRY 886 -- How PI3K with MEK inhibitors eradicates K-Ras tumors -- Blocking the PI3K and MAP Kinase pathways -- Inhibition of S6 kinase in K-Ras tumors.

Access restricted to subscribers.

Mode of access: World Wide Web.

Technical University of Mombasa
Tom Mboya Street, Tudor 90420-80100 , Mombasa Kenya
Tel: (254)41-2492222/3 Fax: 2490571